IDENTIFICATION, ANTIMICROBIAL RESISTANCE AND GENOTYPIC CHARACTERIZATION OF
ENTEROCOCCUS SPP. ISOLATED IN PORTO ALEGRE, BRAZIL

Eduardo André Bender¹ *, Ana Lúcia Peixoto de Freitas², Keli Cristine Reiter², Larissa Lutz³, Afonso Luís Barth²,³

¹Programa de Pós-Graduação em Ciências Farmacêuticas, Faculdade de Farmácia, Universidade Federal do Rio Grande do Sul, Porto Alegre, RS, Brasil; ²Departamento de Análises, Faculdade de Farmácia, Universidade Federal do Rio Grande do Sul, Porto Alegre, RS, Brasil; ³Unidade de Microbiologia e Biologia Molecular, Serviço de Patologia Clínica, Hospital de Clínicas de Porto Alegre, Porto Alegre, RS, Brasil.

Submitted: September 08, 2008; Returned to authors for corrections: October 14, 2008; Approved: May 03, 2009.

ABSTRACT

In the past two decades the members of the genus Enterococcus have emerged as important nosocomial pathogens worldwide. In the present study, we evaluated the antimicrobial resistance and genotypic characteristics of 203 Enterococcus spp. recovered from different clinical sources from two hospitals in Porto Alegre, Rio Grande do Sul, Brazil. The species were identified by conventional biochemical tests and by an automated system. The genetic diversity of E. faecalis presenting high-level aminoglycoside resistance (HLAR) was assessed by pulsed-field gel electrophoresis of chromosomal DNA after SmaI digestion. The E. faecalis was the most frequent specie (93.6%), followed by E. faecium (4.4%). The antimicrobial resistance profile was: 2.5% to ampicillin, 0.5% to vancomycin, 0.5% teicoplanin, 33% to chloramphenicol, 2% to nitrofurantoin, 66.1% to erythromycin, 66.5% to tetracycline, 24.6% to rifampicin, 30% to ciprofloxacin and 87.2% to quinupristin-dalfopristin. A total of 10.3% of the isolates proved to be HLAR to both gentamicin and streptomycin (HLR-ST/GE), with 23.6% resistant only to gentamicin (HLR-GE) and 37.4% only to streptomycin (HLR-ST). One predominant clonal group was found among E. faecalis HLR-GE/ST. The prevalence of resistance among beta-lactam antibiotics and glycopeptides was very low. However, in this study there was an increased number of HLR Enterococcus which may be spreading intra and inter-hospital.

Key words: Enterococcus, resistance, HLAR, PFGE

*Corresponding Author. Mailing address: Rua Vicente da Fontoura 2895/401, Bairro Rio Branco, Porto Alegre, RS, Brazil. CEP 90640-003. Phone: +512103-2861. Email: eabender@hotmail.com
**INTRODUCTION**

Enterococci have increasingly emerged as a cause of serious nosocomial and community-acquired infections, including bacteremia and endocarditis (1, 19). Bactericidal antimicrobial activity, necessary for the treatment of enterococcal infections, is usually obtained by the synergistic combination of a cell-wall active agent, such as a β-lactams or a glycopeptide, with an aminoglycoside, such as gentamicin or streptomycin (3, 25). Several studies have shown increasing resistance of enterococci to antimicrobial agents such as β-lactams, high-level aminoglycosides and more recently to glycopeptides (11, 24, 25).

The emergence of resistance to glycopeptides among *Enterococcus* spp (GRE) has alarmed the scientific community as there is just a very few treatment options for the GRE. Moreover, the fear exists that *Staphylococcus aureus* may import the *van* genes from *Enterococcus* as this was already demonstrated in *in vitro* experiments (11, 22). Colonization of patients in hospital settings by resistant enterococci has been associated to the microorganism spread from other patients and/or from the environment as preventive measures to contain their spread may be of little success (1, 3, 24).

The use of molecular techniques such as pulsed-field gel electrophoresis (PFGE) for analysis of the occurrence of different clonal groups of *Enterococcus* presenting high-level aminoglycoside resistance in Brazilian hospitals has been consistently reported (7, 12, 18). Nevertheless, there is only scanty information about the routes of transmission of resistant enterococci in hospitals from southern Brazil. Thus, this study aims to update epidemiological data on the occurrence of this microorganism in the city of Porto Alegre by carrying out tests for identification of species, analysis of antimicrobial susceptibility and molecular typing by PFGE.

**MATERIALS AND METHODS**

**Bacterial isolates**

A total of 203 enterococcal isolates recovered from patients receiving medical care in two different hospitals (Hospital de Clínicas de Porto Alegre and Hospital São Lucas da PUC) located at Porto Alegre, southern Brazil, were collected during the period from december 2006 to march 2007. The isolates were obtained from urine (131), secretions (38) blood (18), catheter (4) and other sources (10). Only one isolate per patient was included in the study. All isolates were stored at – 80ºC in BHI broth plus 20% glycerol.

**Identification of enterococcal isolates**

Identification of the isolates to the genus level was performed according to: reaction on Gram staining; cellular morphology; growth and blackening of bile-esculin agar, growth in the presence of 6.5% NaCl; absence of catalase; and presence of pyrrolidonyl arylamidase (PYR). Identification to species level was performed by a panel of biochemical tests (9, 10). Species were also identified by the VITEK 2 system (software version 1.02) (BioMerieux) according to the manufacturer’s recommendations.

**Susceptibility testing**

Antibiotic susceptibility studies were performed by disc diffusion method (Kirby-Bauer) according to the Clinical and Laboratory Standard Institute (CLSI 2007) (5) for the following antibiotics: ampicillin, vancomycin, teicoplanin, rifampicin, erythromycin, tetracycline, cloranfenicol, ciprofloxacin, quinupristin-dalfopristin, nitrofurantoin (Oxoid Ltd, Basingstoke, UK). High level aminoglycoside resistance was determined by two different methods: standard agar screening and disc diffusion. Standard agar screening for HLR is was carried out on Mueller-Hinton agar plates (Oxoid
Charaterization of *Enterococcus* spp.

Lrd, Basingstoke, UK) with either 500µg/mL gentamicin (Oxoid Ltd) or 2000µg/mL streptomycin (Oxoid Ltd). The disc diffusion screening method was performed on Mueller-Hinton agar (BBL Microbiology Systems) using discs with 120µg/mL of gentamicin and 300µg/mL of streptomycin (Oxoid Ltd). The correlation between the results of the above methods was determined by the kappa coefficient (SPSS v.15.0).

Isolates were tested for β-lactamase production by the chromogenic cephalosporin (nitrocefin) disk method (Becton Dickinson Diagnostic Systems, Sparks, Maryland, USA). *Enterococcus faecalis ATCC 29212* and *Staphylococcus aureus ATCC 25923* were used as quality control strains for all tests of susceptibility.

**DNA extraction and restriction fragment analysis by PFGE**

Chromosomal DNA was obtained as described by Kaufmann (15). Purified DNA was digested with the restriction enzyme *SmaI* (GIBCO BRL, New York) and separated by PFGE in 1% agarose gels, using a CHEF-DRII system (Bio-Rad Laboratories, Richmond, Calif.). The pulse time was increased from 5 to 35s, over 22 hours at 5,9V/cm at 11ºC and a 120º angle. Lambda ladder of 48,5 Kb concatamers (New England BioLabs, Beverly, MA, UK) were used as molecular weight markers. Gels were stained with ethidium bromide and photographed under UV light. Analysis of DNA restriction profiles was performed by visual inspection according to Tenover *et al.* (23).

**RESULTS**

It was possible to identify 5 species among the 203 isolates of *Enterococcus* in our study: *E. faecalis* (93.6%), *E. faecium* (4.4%), *E. casseliflavus* (1%), *E. gallinarum* (0.5%) and *E. hirae* (0.5%).

The majority of isolates were highly susceptible to several antibiotics (ampicillin, vancomycin, teicoplanin, and nitrofurantoin) by the disc diffusion method. High resistance rates were observed only to erythromycin, tetracycline and quinupristin-dalfopristin (Table 1). It is of note that only five enterococci were resistant to ampicillin and four of them were identified as *E. faecium*. As expected, the presence of *E. faecalis* resistant to this β-lactam antibiotic was very rare in our study. None of the isolates displayed β-lactamase activity.

We found only three isolates non-susceptible to vancomycin: one isolate, which was fully resistant to vancomycin, was identified as *E. faecalis*; and the other two isolates, with intermediary resistance to vancomycin, were identified as *E. casseliflavus* and *E. gallinarum*.

High-level resistance to gentamicin or streptomycin was detected by the disc diffusion in 23.6% and 37.4% of isolates, respectively. Combined high-level streptomycin and gentamicin resistance (HLR-GE/ST) was detected in 10.3% of isolates. *E. faecium* isolates had a higher rate of combined resistance (streptomycin and gentamicin) than the other species. Excellent correlation was observed between the high-level disc test and the agar screening test in the detection of HLR (Kappa coefficient was 0.89).

It was possible to compare the resistance rates of HLR and non-RLR isolates to other antibiotics and the HLR proved to be more resistant to all non-β-lactams.

The genetic profile of 17 isolates of *E. faecalis* HLR-GE/ST was examined and we found the existence of 8 isolates with identical profile (clone A). Five isolates proved to be highly correlated to the clone A and were considered to belong to the this major clonal group (Fig. 1). The other 4 isolates were all unrelated.
Table 1. Antimicrobial susceptibility profile according to disc diffusion method among 203 enterococcal isolates in two hospitals in the city of Porto Alegre, Brazil.

| Antimicrobial agents       | Susceptible N (%) | Intermediate n (%) | Resistant n (%) |
|----------------------------|-------------------|--------------------|-----------------|
| Ampicillin                 | 198 (97,5)        | NA                 | 5 (2,5)         |
| Streptomycin (HLR-St)<sup>b</sup> | 130 (64,0)      | 0 (0)              | 73 (36,0)       |
| Gentamicin (HLR-Ge)<sup>c</sup> | 156 (76,8)       | 2 (1,0)            | 45 (22,2)       |
| Vancomycin                 | 200 (98,5)        | 2 (1,0)            | 1 (0,5)         |
| Teicoplanin                | 202 (99,5)        | 0 (0)              | 1 (0,5)         |
| Cloranfenicol              | 131 (64,5)        | 5 (2,5)            | 67 (33,0)       |
| Nitrofurantoin             | 195 (96)          | 4 (2,0)            | 4 (2,0)         |
| Erythromycin               | 15 (7,4)          | 62 (30,5)          | 126 (62,1)      |
| Tetracycline               | 68 (33,5)         | 4 (2,0)            | 131 (64,5)      |
| Rifampicin                 | 71 (35,0)         | 82 (40,4)          | 50 (24,6)       |
| Ciprofloxacin              | 114 (56,2)        | 28 (13,8)          | 61 (30,0)       |
| Quinupristin-dalfopristin<sup>d</sup> | 12 (5,9)     | 14 (6,9)           | 177 (87,2)      |

<sup>a</sup> Not applicable  
<sup>b</sup> HLR-St: high-level resistance to streptomycin  
<sup>c</sup> HLR-Ge: high-level resistance to gentamicin  
<sup>d</sup> High difference of resistance among enterococci species: *E. faecium* 11.1% resistant and *E. faecalis* 91% of resistance

![PFGE profiles](image_url)

Figure 1. PFGE profiles of *SmaI*-digested chromosomal DNA of HLR-GE/ST *Enterococcus faecalis* isolates belonging to major clonal group A. λ lambda phage DNA markers; lanes 1-7: isolates from HSL; lanes 8-9: isolates from HCPA.

We also analyzed 18 isolates of *E. faecalis* presenting high-level resistance only to gentamicin (HLR-GE) by PFGE. No predominant clonal group was found among HLR-GE as 11 clones were identified. Noteworthy one clone (representing only one isolate) was highly related to the predominant clone A of HLR-GE/ST (subclone A6) (Fig. 2).

The only vancomycin-resistant *Enterococcus* isolate (VRE) identified in this study was also resistant to ampicillin, teicoplanin, HLR-GE/ST and presented a unique PFGE profile (Fig. 2).
Characterization of Enterococcus spp.

Figure 2. PFGE profiles of Smal-digested chromosomal DNA of HLR-GE Enterococcus faecalis. λ lambda phage DNA markers; lanes 1-9: isolates belonging to different clonal groups (lanes 1-6: isolates from HCPA; lanes 7-9: isolates from HSL. Lane 2: isolate resistant to vancomycin and teicoplanin).

DISCUSSION

In this study, we have evaluated the frequency of species, the patterns of antimicrobial resistance and the molecular epidemiology of enterococci in clinical specimens obtained from two different hospitals of the city of Porto Alegre, Brazil.

Several species of enterococci are currently recognized, but 85-95% of enterococcal infections are caused by E. faecalis, and 5-10% are caused by E. faecium (3, 6, 11, 19). This study showed that E. faecalis was the most prevalent specie (93.6%) and other species were found only in a minority of cases [E. faecium (4.4%), E. casseliflavus (1%), E. gallinarum (0.5%) e E. hirae (0.5%)]. Although a few studies (14, 22) have documented an increase in the prevalence of E. faecium, in this study the prevalence of this specie was considerable low. This may be due to the fact that high prevalence of E. faecium is usually related to increase resistance to vancomycin which was not the case in this study.

Results of antimicrobial susceptibility tests by the disk diffusion method showed that vast the majority of the isolates (97.5%) in this study were susceptible to ampicillin. In fact, only one E. faecalis was resistant to ampicillin as the other 4 ampicillin-resistant isolates belonged to the E. faecium species. This high susceptibility rate to ampicillin is similar to rates from other studies (7, 13, 16) and confirm that E. faecalis resistant to ampicillin is also quite rare in our region (3, 8, 22).

We found only one isolate resistant to vancomycin and teicoplanin, which was identified as E. faecalis, and this confirms that the prevalence of VRE is still very low in clinical isolates from patients with infections in our region. In fact, VRE is more frequent in studies that assess colonization of patients (1, 8).

The two isolates with intermediary resistance to vancomycin, E. casseliflavus and E. gallinarum, were not further investigated in this study as these species have low clinical impact and are not implicated in epidemic outbreaks and thus, have small importance for the control of intra-hospital infections (3, 5, 8, 11, 14).

Conversely, we found high-level resistance to streptomycin or gentamicyn in 37.4% and 23.6%, respectively, while the resistance to both aminoglycosides (HLR-GE/ST) was 10.3%. This finding is a cause of concern, because it may indicate a major resistance problem in our hospitals in the near future. However, the resistance to gentamycin in high levels is of more importance than the resistance in high levels to streptomycin as HLR-GE predicts
resistance to all other aminoglycosides, except streptomycin (22, 25). Similar resistance rates of HLAR have been reported in Cuba by Quiñones et al. (20) and in Peru by Kaçmaz & Aksoy (14). In Brazil, studies in the state of Paraná (2) and in Rio Grande do Sul (13) presented lower rates of HLAR. It is of note that a previous study performed in the same hospitals indicated a very similar HLR/GE resistance rate but a HLR/ST considerable lower (15.8%) (6, 7).

Alternative antibiotics to treat infections by Enterococcus also showed high rates of resistance in vitro: erythromycin (62.1% of resistance) and tetracycline (64.5%), which makes them unsuitable for empirical antimicrobial therapy.

On the other hand, the isolates of enterococci in this study displayed moderate resistance to rifampicin (24.6%), chloramphenicol (33%) and ciprofloxacin (30%) and low resistance only to nitrofurantoin (2%). These antimicrobials may, therefore, be indicated for empirical treatment of urinary tract infection due to Enterococcus sp in our region as previously suggested (19).

The resistance to quinupristin-dalfopristin (Q/D) was 87.2%, but this cannot be considered representative of this genus as we found a low resistance among E. faecium (11.1%) and a high level among E. faecalis (91%). In fact, it is well known that E. faecalis is intrinsically resistant to Q/D and this was confirmed in our results. However, Q/D has been used successfully to treat infections caused by E. faecium despite some studies describing the emergence of resistance during the therapy. (4, 17, 22).

As demonstrated by molecular typing, there was a predominant clone among isolates of E. faecalis HLR-GE/ST. As this clone was obtained from isolates of patients attending two hospitals (HCPA and HSL) during a short time-frame period, it is possible to consider that there was an intra and inter-hospital dissemination of E. faecalis HLR-GE/ST. This is the first report of a major clonal E. faecalis HLR-GE/ST spread in two hospitals of Porto Alegre although, previously, only a clone of E. faecalis HLR-GE had been reported (7). In fact, we found a considerable genetic diversity among E. faecalis HLR-GE in our study. Noteworthy, clonal dissemination of E. faecalis HLR-GE/ST has already been described in the state of Rio de Janeiro in previous years (18).

The only E. faecalis resistant to vancomycin identified in our study showed different genetic profile from the predominant clone of E. faecalis HLR-GE/ST. Therefore, we could infer that the high prevalence of this clone would not lead to selection of VRE strains in the two hospitals evaluated.

Moreover, it was possible to compare the VRE genetic profile from this study with the profile of the clonal VRE from an outbreak describe in previous years in the city of Porto Alegre (21) and they proved to be the same (data not shown). This result confirms that the previous VRE reported in Porto Alegre had not spread to hospitalized patients with infection due to enterococci.

The identification of a major clonal group in E. faecalis HLR-GE/ST, draws attention to the increasing need for control measures to avoid horizontal transmission, since the enterococci currently represent a serious problem in health institutions, especially because of the possibility of spread from healthy carriers and the lack of effective treatment options.

ACKNOWLEDGEMENTS
RESUMO

Identificação, resistência antimicrobiana e caracterização genotípica de Enterococcus spp. isolados em Porto Alegre, Brasil

Nas últimas duas décadas os membros do gênero Enterococcus emergiram como importantes patógenos nosocomiais ao redor do mundo. No presente estudo, nós avaliamos a resistência antimicrobiana e as características genotípicas de 203 Enterococcus spp. obtidos de diferentes fontes clínicas em dois hospitais de Porto Alegre, Rio Grande do Sul, Brasil. As espécies foram identificadas por testes bioquímicos convencionais e por um sistema automatizado. A diversidade genética de *E. faecalis* demonstrando resistência à altos níveis de aminoglicosídeos (HLR) foi avaliada através da análise do DNA cromossômico após digestão com a enzima *Smal*, seguido por eletroforese em campo pulsado. O *E. faecalis* foi a espécie mais frequente (93,6%), seguido por *E. faecium* (4,4%). O perfil de resistência antimicrobiana foi: 2,5% para ampicilina, 0,5% para vancomicina, 0,5% para teicoplanina, 33% para cloranfenicol, 2% para nitrofurantoína, 66,1% para eritromicina, 66,5% para tetraciclina, 24,6% para rifampicina, 30% para ciprofloxacino e 87,2% para quinupristina-dalfopristina. Um total de 10,3% dos isolados apresentaram HLR para ambos gentamicina e estreptomicina (HLR-GE/ST). A prevalência de resistência a antibióticos β-lactâmicos, e em particular aos glicopeptídeos, foi muito baixa. Entretanto, neste estudo, houve um número crescente de Enterococcus HLR que podem estar se disseminando intra e interhospitais.

Palavras-chave: Enterococcus, resistência, HLR, PFGE

REFERENCES

1. Bazet, C.; Blanco, J.; Seija, V.; Palácio, R. (2005). Enterococos resistentes a vancomicina. Un problema emergente en Uruguay. *Rev. Med. Urug* 21: 151-158.
2. Bedendo, J.; Pignatari, A.C.C. (2000). Typing of Enterococcus faecium by polymerase chain reaction and pulsed field gel electrophoresis. *Braz J Med Biol Res*, v. 33, p. 1269-1274.
3. Cetinkaya, Y.; Falk, P.; Mayhall, C.G. (2000). Vancomycin-Resistant Enterococci. *Clin Microbiol Rev* 13: 686-707.
4. Chow, J.W.; Donahedian, S.M.; Zervos, M.J. (1997). Emergence of increased resistance to quinupristin/dalfopristin during therapy for Enterococcus faecium bacteremia. *Clin Infect Dis* 24: 90-91.
5. CLSI – Clinical and Laboratory Standards Institute. (2007). *Performance Standards for Antimicrobial Susceptibility Testing; Sixteenth Informational Supplement – M100-S17.* CLSI.
6. D’Azevedo, P.A.; Dias, C.A.G.; Lemos, S.B.; Bittencourt, J.A.F.; Teixeira, L.M. (2004). Antimicrobial susceptibility among Enterococcus isolates from the city of Porto Alegre, RS, Brazil. *Braz. J. Microbiol* 35: 199-204.
7. D’Azevedo, P.A.; Dias, C.A.G.; Teixeira, L.M. (2006). Genetic diversity and antimicrobial resistance of enterococcal isolates from southern region of Brazil. *Rev Inst Med Trop Sao Paulo* 48: 11-16.
8. Deshpande, L.M.; Fritsche, T.R.; Moet, G.J.; Biedenbach, D.J.; Jones, R.N. (2007). Antimicrobial resistance and molecular epidemiology of vancomycin-resistant enterococci from North America and Europe: a report from the SENTRY antimicrobial surveillance program. *Diagn Microbiol Infect Dis* 58: 163-170.
9. Facklam, R.R.; Collins, M.D. (1989). Identification of Enterococcus species isolated from human infections by a conventional test scheme. *J Clin Microbiol* 27: 731-734.
10. Facklam, R.R.; Carvalho, M.G.; Teixeira, L. (2002). History, taxonomy, biochemical characteristics, and antibiotic susceptibility
testing of enterococci. In: Gilmore M. S. The enterococci pathogenesis, molecular biology, and antibiotic resistance. Washington, DC: American Society for Microbiology.

11. Facklam, R.R.; Carvalho, M.G.S.; Teixeira, L.M. (2007). *Enterococcus*. In: Murray PR, Baron EJ, Pfaller MA, Jorgensen JH, Landry ML. *Manual of Clinical Microbiology*. v. 1, 9th ed. Washington, American Society for Microbiology, USA, p. 430-442.

12. Furtado, G.H.C.; Martins, S.T.; Coutinho, A.P.; Soares, G.M.M.; Wey, S.B.; Medeiros, E.A.S. (2005). Incidência de *Enterococcus* resistente à vancomicina em um hospital universitário no Brasil. *Rev. Saúde públic*. 39: 41-46.

13. Hörner, R.; Liscano, M.G.H.; Maraschin, M.M.; Salla, A.; Meneghetti, B.; Forno, N.F. D.; Righi, R.A. (2005). Suscetibilidade antimicrobiana entre amostras de *Enterococcus* isoladas no Hospital Universitário de Santa Maria. *J. Bras. Patol Med Lab*. v. 41, n. 6, p. 391-395.

14. Kaçmaz, B.; Aksoy, A. (2005). Antimicrobial resistance of enterococci in Turkey. *Int J Antimicrob Agents*. 25: 535-538.

15. Kaufmann, M.E. (1998). Pulsed-field gel electrophoresis. In: Woodford N, Johnson AP. *Molecular Bacteriology: Protocols and Clinical Applications*. New Jersey: Humana Press Inc, p.33-62.

16. Kobayashi, I.; Muraoka, H.; Iyoda, T.; Nishida, M.; Hasegawa, M.; Yamaguchi, K. (2004). Antimicrobial susceptibility testing of vancomycin-resistant *Enterococcus* by VITEK 2 system, and comparison with two NCCLS reference methods. *J Med Microbiol*. 53: 1229-1232.

17. Mendes, C.; Sinto, S.I.; Hsiung, A.; Oplastil, C.; Teixeira, L.; Segura, A.; Souza, D.; Barth, A.L.; Nicodemo, A.C. (2002). Atividade antimicrobiana *in vitro* de quinupristina/dalfopristina para cocos Gram-positivos isolados de cinco centros brasileiros: resultado do estudo de vigilância L-SMART. *J Bras Patol Med Lab*. 38: 191-197.

18. Mondino, S.B.; Castro, A.C.D.; Mondino, P.J.J.; Carvalho, M.G.S.; Silva, K.M.F.; Teixeira, L.M. (2003). Phenotypic and genotyping characterization of clinical and intestinal Enterococci isolated from inpatients and outpatients in two Brazilian Hospitals. *Microb Drug Resist*. 9: 167-174.

19. Murray, B.E. (2000). Vancomycin-resistant enterococcal infections. *New Engl J Med*. 342: 710-721.

20. Quiñones, D.; Goñi, P.; Rubio, M.C.; Duran, E.; Gömez-Luz, R. (2005). Enterococci spp. isolated from Cuba: species frequency of occurrence and antimicrobial susceptibility profile, *Diagn Microbiol Infect Dis.*, v. 51, p. 63-67.

21. Sandri, A.M. (2004). *Enterococcus* spp. resistente à vancomicina: tipagem molecular, caracterização clínica e associação com mortalidade. Porto Alegre, Brasil, 85p. (M.Sc. Dissertation. Programa de Pós-Graduação em Medicina. UFRGS).

22. Shepard, B.D.; Gilmore, M.S. (2002). Antibiotic-resistant enterococci: mechanisms and dynamics of drug introduction and resistance. *Microb Infect*. 4: 215-224.

23. Tenover, F.C.; Arbeit, R.D.; Goering, R.V.; Mickelsen, P.A.; Murray, B.E.; Persing, D.H.; Swaminathan, B. (1995). Interpreting chromosomal DNA restriction patterns produced by pulsed-field gel electrophoresis: criteria for bacterial strain typing. *J Clin Microbiol*. 33: 2233-2239.

24. Zanella, R.C.; Lima, M.J.C.; Tagani, L.S.; Hitomi, A.; Brandileone, A.C.; Palazzo, I.C.; Darini, A.L.C. (2006). Emergence of vanB phenotype-vanA genotype in vancomycin-resistant enterococci in Brazilian hospital. *Braz J Microbiol*. 37: 117-118

25. Zarrili, R.; Tripodi, M.F.; Podolo, A.D.; Fortunato, R.; Bagattini, M.; Crispino, M.; Florio, A.; Triassi, M.; Utili, R. (2005). Molecular epidemiology of high-level aminoglycoside-resistant enterococci isolated from patients in a university hospital in southern Italy. *J Antimicrob Chemother*. 56: 827-835.